Mutual of America Capital Management LLC Decreases Stock Position in Kenvue Inc. $KVUE

Mutual of America Capital Management LLC lessened its stake in Kenvue Inc. (NYSE:KVUE) by 25.2% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 219,849 shares of the company’s stock after selling 73,973 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Kenvue were worth $4,601,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in KVUE. GAMMA Investing LLC boosted its stake in shares of Kenvue by 33.2% in the 1st quarter. GAMMA Investing LLC now owns 24,778 shares of the company’s stock valued at $594,000 after buying an additional 6,169 shares during the period. Cambridge Investment Research Advisors Inc. lifted its stake in Kenvue by 4.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock worth $2,545,000 after acquiring an additional 4,034 shares during the last quarter. Continuum Advisory LLC lifted its position in shares of Kenvue by 2,071.1% during the 1st quarter. Continuum Advisory LLC now owns 1,954 shares of the company’s stock worth $47,000 after purchasing an additional 1,864 shares during the last quarter. Oppenheimer & Co. Inc. lifted its position in shares of Kenvue by 5.3% during the 1st quarter. Oppenheimer & Co. Inc. now owns 172,255 shares of the company’s stock worth $4,131,000 after purchasing an additional 8,693 shares during the last quarter. Finally, Asset Management One Co. Ltd. lifted its holdings in Kenvue by 6.9% during the 1st quarter. Asset Management One Co. Ltd. now owns 801,376 shares of the company’s stock worth $19,217,000 after buying an additional 51,796 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 1.8%

Shares of NYSE:KVUE opened at $15.20 on Thursday. The stock has a market cap of $29.16 billion, a P/E ratio of 20.53, a P/E/G ratio of 2.15 and a beta of 0.72. The firm has a fifty day moving average price of $18.15 and a 200 day moving average price of $20.89. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. Kenvue Inc. has a 1-year low of $14.05 and a 1-year high of $25.17.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same quarter in the prior year, the firm earned $0.32 earnings per share. The business’s quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a yield of 5.5%. The ex-dividend date of this dividend was Wednesday, August 13th. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is 112.16%.

Analysts Set New Price Targets

A number of analysts have issued reports on KVUE shares. Zacks Research raised Kenvue to a “strong sell” rating in a report on Monday, August 11th. Evercore ISI decreased their target price on Kenvue from $23.00 to $18.00 and set an “in-line” rating for the company in a research note on Tuesday, September 23rd. Royal Bank Of Canada reduced their price objective on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research report on Friday, August 8th. The Goldman Sachs Group reduced their price objective on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a research report on Thursday, October 2nd. Finally, Canaccord Genuity Group reduced their price target on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $21.18.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.